Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1996 Mar;70(3):1953–1960. doi: 10.1128/jvi.70.3.1953-1960.1996

Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine.

S P Mossman 1, F Bex 1, P Berglund 1, J Arthos 1, S P O'Neil 1, D Riley 1, D H Maul 1, C Bruck 1, P Momin 1, A Burny 1, P N Fultz 1, J I Mullins 1, P Liljeström 1, E A Hoover 1
PMCID: PMC190024  PMID: 8627721

Abstract

Infection of pigtail macaques with SIVsmmPBj14, biological clone 3 (SIV-PBj14-bc13), produces an acute and usually fatal shock-like syndrome 7 to 14 days after infection. We used this simian immunodeficiency virus (SIV) model as a rapid and rigorous challenge to evaluate the efficacy of two SIV Env vaccine strategies. Groups of four pigtail macaques were immunized four times over a 25-week span with either a recombinant Semliki Forest virus expressing the SIV-PBj14 Env gp160 (SFV-SIVgp160) or purified recombinant SIV-PBj14 gp120 (rgp120) in SBN-1 adjuvant. Antibody titers to SIV Env developed in all immunized animals (mean peak titers prior to challenge, 1:1,700 for SFV-SIV gp 160 and 1:10,500 for rgp120), but neither neutralizing antibodies nor SIV-specific T-cell proliferative responses were detectable in any of the vaccinees. All macaques were challenged with a 100% infectious, 75% fatal dose of SIV-PBj14-bc13 at week 26. Three of four control animals died of acute SIV-PBj14 syndrome on days 12 and 13. By contrast, all four SFV-SIVgp160-immunized animals and three of the four rgp120-immunized animals were protected from lethal disease. While all virus-challenged animals became infected, symptoms of the SIV-PBj14 syndrome were more severe in controls than in vaccinees. Mean virus titers in plasma at 13 days postchallenge were approximately 10-fold lower in vaccinated than control animals. However, there was no apparent correlation between survival and levels of peripheral blood mononuclear cell-associated culturable virus, provirus load, or any antiviral immunologic parameter examined. The results indicate that while immunization with SFV-SIVgp160 and rgp120 did not protect against virus infection, these Env vaccines did lower the virus load in plasma and protect against the lethal SIV-PBj14 challenge.

Full Text

The Full Text of this article is available as a PDF (296.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abimiku A. G., Franchini G., Tartaglia J., Aldrich K., Myagkikh M., Markham P. D., Chong P., Klein M., Kieny M. P., Paoletti E. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nat Med. 1995 Apr;1(4):321–329. doi: 10.1038/nm0495-321. [DOI] [PubMed] [Google Scholar]
  2. Ahmad S., Lohman B., Marthas M., Giavedoni L., el-Amad Z., Haigwood N. L., Scandella C. J., Gardner M. B., Luciw P. A., Yilma T. Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus. AIDS Res Hum Retroviruses. 1994 Feb;10(2):195–204. doi: 10.1089/aid.1994.10.195. [DOI] [PubMed] [Google Scholar]
  3. Berglund P., Sjöberg M., Garoff H., Atkins G. J., Sheahan B. J., Liljeström P. Semliki Forest virus expression system: production of conditionally infectious recombinant particles. Biotechnology (N Y) 1993 Aug;11(8):916–920. doi: 10.1038/nbt0893-916. [DOI] [PubMed] [Google Scholar]
  4. Berman P. W., Gregory T. J., Riddle L., Nakamura G. R., Champe M. A., Porter J. P., Wurm F. M., Hershberg R. D., Cobb E. K., Eichberg J. W. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature. 1990 Jun 14;345(6276):622–625. doi: 10.1038/345622a0. [DOI] [PubMed] [Google Scholar]
  5. Cohen J. AIDS vaccine research. A new goal: preventing disease, not infection. Science. 1993 Dec 17;262(5141):1820–1821. doi: 10.1126/science.8266069. [DOI] [PubMed] [Google Scholar]
  6. Daniel M. D., Kirchhoff F., Czajak S. C., Sehgal P. K., Desrosiers R. C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 1992 Dec 18;258(5090):1938–1941. doi: 10.1126/science.1470917. [DOI] [PubMed] [Google Scholar]
  7. Daniel M. D., Mazzara G. P., Simon M. A., Sehgal P. K., Kodama T., Panicali D. L., Desrosiers R. C. High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection. AIDS Res Hum Retroviruses. 1994 Jul;10(7):839–851. doi: 10.1089/aid.1994.10.839. [DOI] [PubMed] [Google Scholar]
  8. Deen K. C., McDougal J. S., Inacker R., Folena-Wasserman G., Arthos J., Rosenberg J., Maddon P. J., Axel R., Sweet R. W. A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature. 1988 Jan 7;331(6151):82–84. doi: 10.1038/331082a0. [DOI] [PubMed] [Google Scholar]
  9. Dewhurst S., Embretson J. E., Anderson D. C., Mullins J. I., Fultz P. N. Sequence analysis and acute pathogenicity of molecularly cloned SIVSMM-PBj14. Nature. 1990 Jun 14;345(6276):636–640. doi: 10.1038/345636a0. [DOI] [PubMed] [Google Scholar]
  10. Emini E. A., Schleif W. A., Nunberg J. H., Conley A. J., Eda Y., Tokiyoshi S., Putney S. D., Matsushita S., Cobb K. E., Jett C. M. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature. 1992 Feb 20;355(6362):728–730. doi: 10.1038/355728a0. [DOI] [PubMed] [Google Scholar]
  11. Fultz P. N., McClure H. M., Anderson D. C., Switzer W. M. Identification and biologic characterization of an acutely lethal variant of simian immunodeficiency virus from sooty mangabeys (SIV/SMM). AIDS Res Hum Retroviruses. 1989 Aug;5(4):397–409. doi: 10.1089/aid.1989.5.397. [DOI] [PubMed] [Google Scholar]
  12. Fultz P. N., Zack P. M. Unique lentivirus--host interactions: SIVsmmPBj14 infection of macaques. Virus Res. 1994 May;32(2):205–225. doi: 10.1016/0168-1702(94)90042-6. [DOI] [PubMed] [Google Scholar]
  13. Gilljam G. Envelope glycoproteins of HIV-1, HIV-2, and SIV purified with Galanthus nivalis agglutinin induce strong immune responses. AIDS Res Hum Retroviruses. 1993 May;9(5):431–438. doi: 10.1089/aid.1993.9.431. [DOI] [PubMed] [Google Scholar]
  14. Hart M. K., Palker T. J., Matthews T. J., Langlois A. J., Lerche N. W., Martin M. E., Scearce R. M., McDanal C., Bolognesi D. P., Haynes B. F. Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys. J Immunol. 1990 Oct 15;145(8):2677–2685. [PubMed] [Google Scholar]
  15. Hirsch V. M., Goldstein S., Hynes N. A., Elkins W. R., London W. T., Zack P. M., Montefiori D., Johnson P. R. Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine. J Infect Dis. 1994 Jul;170(1):51–59. doi: 10.1093/infdis/170.1.51. [DOI] [PubMed] [Google Scholar]
  16. Hu S. L., Abrams K., Barber G. N., Moran P., Zarling J. M., Langlois A. J., Kuller L., Morton W. R., Benveniste R. E. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science. 1992 Jan 24;255(5043):456–459. doi: 10.1126/science.1531159. [DOI] [PubMed] [Google Scholar]
  17. Hu S. L., Abrams K., Misher L., Stallard V., Moran P., Zarling J. M., Langlois A. J., Kuller L., Morton W. R., Benveniste R. E. Evaluation of protective efficacy of recombinant subunit vaccines against simian immunodeficiency virus infection of macaques. J Med Primatol. 1992 Feb-May;21(2-3):119–125. [PubMed] [Google Scholar]
  18. Israel Z. R., Dean G. A., Maul D. H., O'Neil S. P., Dreitz M. J., Mullins J. I., Fultz P. N., Hoover E. A. Early pathogenesis of disease caused by SIVsmmPBj14 molecular clone 1.9 in macaques. AIDS Res Hum Retroviruses. 1993 Mar;9(3):277–286. doi: 10.1089/aid.1993.9.277. [DOI] [PubMed] [Google Scholar]
  19. Israel Z. R., Edmonson P. F., Maul D. H., O'Neil S. P., Mossman S. P., Thiriart C., Fabry L., Van Opstal O., Bruck C., Bex F. Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines. J Virol. 1994 Mar;68(3):1843–1853. doi: 10.1128/jvi.68.3.1843-1853.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lewis M. G., Elkins W. R., McCutchan F. E., Benveniste R. E., Lai C. Y., Montefiori D. C., Burke D. S., Eddy G. A., Shafferman A. Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection. Vaccine. 1993 Oct;11(13):1347–1355. doi: 10.1016/0264-410x(93)90106-8. [DOI] [PubMed] [Google Scholar]
  21. Li S., Polonis V., Isobe H., Zaghouani H., Guinea R., Moran T., Bona C., Palese P. Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1. J Virol. 1993 Nov;67(11):6659–6666. doi: 10.1128/jvi.67.11.6659-6666.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Liljeström P. Alphavirus expression systems. Curr Opin Biotechnol. 1994 Oct;5(5):495–500. doi: 10.1016/0958-1669(94)90063-9. [DOI] [PubMed] [Google Scholar]
  23. Liljeström P., Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N Y) 1991 Dec;9(12):1356–1361. doi: 10.1038/nbt1291-1356. [DOI] [PubMed] [Google Scholar]
  24. Marthas M. L., Sutjipto S., Higgins J., Lohman B., Torten J., Luciw P. A., Marx P. A., Pedersen N. C. Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV. J Virol. 1990 Aug;64(8):3694–3700. doi: 10.1128/jvi.64.8.3694-3700.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Murphey-Corb M., Martin L. N., Davison-Fairburn B., Montelaro R. C., Miller M., West M., Ohkawa S., Baskin G. B., Zhang J. Y., Putney S. D. A formalin-inactivated whole SIV vaccine confers protection in macaques. Science. 1989 Dec 8;246(4935):1293–1297. doi: 10.1126/science.2555923. [DOI] [PubMed] [Google Scholar]
  26. Murphey-Corb M., Montelaro R. C., Miller M. A., West M., Martin L. N., Davison-Fairburn B., Ohkawa S., Baskin G. B., Zhang J. Y., Miller G. B. Efficacy of SIV/deltaB670 glycoprotein-enriched and glycoprotein-depleted subunit vaccines in protecting against infection and disease in rhesus monkeys. AIDS. 1991 Jun;5(6):655–662. doi: 10.1097/00002030-199106000-00003. [DOI] [PubMed] [Google Scholar]
  27. Paul N. L., Marsh M., McKeating J. A., Schulz T. F., Liljeström P., Garoff H., Weiss R. A. Expression of HIV-1 envelope glycoproteins by Semliki Forest virus vectors. AIDS Res Hum Retroviruses. 1993 Oct;9(10):963–970. doi: 10.1089/aid.1993.9.963. [DOI] [PubMed] [Google Scholar]
  28. Planelles V., Haigwood N. L., Marthas M. L., Mann K. A., Scandella C., Lidster W. D., Shuster J. R., Van Kuyk R., Marx P. A., Gardner M. B. Functional and immunological characterization of SIV envelope glycoprotein produced in genetically engineered mammalian cells. AIDS Res Hum Retroviruses. 1991 Nov;7(11):889–898. doi: 10.1089/aid.1991.7.889. [DOI] [PubMed] [Google Scholar]
  29. Shafferman A., Jahrling P. B., Benveniste R. E., Lewis M. G., Phipps T. J., Eden-McCutchan F., Sadoff J., Eddy G. A., Burke D. S. Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7126–7130. doi: 10.1073/pnas.88.16.7126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Shafferman A., Lewis M. G., McCutchan F. E., Benveniste R. E., Jahrling P. B., Hickman R. L., Lai C. Y., Burke D. S., Eddy G. A. Vaccination of macaques with SIV conserved envelope peptides suppressed infection and prevented disease progression and transmission. AIDS Res Hum Retroviruses. 1992 Aug;8(8):1483–1487. doi: 10.1089/aid.1992.8.1483. [DOI] [PubMed] [Google Scholar]
  31. Shen L., Chen Z. W., Miller M. D., Stallard V., Mazzara G. P., Panicali D. L., Letvin N. L. Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes. Science. 1991 Apr 19;252(5004):440–443. doi: 10.1126/science.1708168. [DOI] [PubMed] [Google Scholar]
  32. Urlaub G., Chasin L. A. Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. Proc Natl Acad Sci U S A. 1980 Jul;77(7):4216–4220. doi: 10.1073/pnas.77.7.4216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Vaslin B., Le Grand R., Vogt G., Benveniste O., Gras G., Roques P., Stoeckel P., Salk P. L., Salk J., Dormont D. Induction of humoral and cellular immunity to simian immunodeficiency virus: what are the requirements for protection? Vaccine. 1994 Sep;12(12):1132–1140. doi: 10.1016/0264-410x(94)90184-8. [DOI] [PubMed] [Google Scholar]
  34. Wigler M., Perucho M., Kurtz D., Dana S., Pellicer A., Axel R., Silverstein S. Transformation of mammalian cells with an amplifiable dominant-acting gene. Proc Natl Acad Sci U S A. 1980 Jun;77(6):3567–3570. doi: 10.1073/pnas.77.6.3567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Yasutomi Y., Koenig S., Woods R. M., Madsen J., Wassef N. M., Alving C. R., Klein H. J., Nolan T. E., Boots L. J., Kessler J. A. A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge. J Virol. 1995 Apr;69(4):2279–2284. doi: 10.1128/jvi.69.4.2279-2284.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Zhou X., Berglund P., Rhodes G., Parker S. E., Jondal M., Liljeström P. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine. 1994 Dec;12(16):1510–1514. doi: 10.1016/0264-410x(94)90074-4. [DOI] [PubMed] [Google Scholar]
  37. Zhou X., Berglund P., Zhao H., Liljeström P., Jondal M. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):3009–3013. doi: 10.1073/pnas.92.7.3009. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES